从正邪理论探讨肿瘤免疫微环境及中医辨治思路

王郅宜; 高磊; 胡少朴; 李泉旺

doi:10.3969/j.issn.2095-6606.2023.06.016

您当前的位置：

首页 >

文章列表页 >

从正邪理论探讨肿瘤免疫微环境及中医辨治思路

理论探讨 | 更新时间：2023-12-08

- 从正邪理论探讨肿瘤免疫微环境及中医辨治思路
- Discussion on tumor immune microenvironment and the application of traditional Chinese medicine based on the theory of "healthy and evil qi"
- 现代中医临床 2023年30卷第6期页码：71-75
- 作者机构：
  
  1.北京中医药大学　北京　100029
  2.北京中医药大学东方医院
- 作者简介：
  
  王郅宜，女，在读博士生
  #李泉旺，男，硕士，主任医师，E-mail：quanwangli@126.com
- 基金信息：
  
  国家自然科学基金面上项目(82174458);中央高校基本科研业务费专项资金资助项目(2020－JYB-ZDGG－127)
- DOI：10.3969/j.issn.2095-6606.2023.06.016
  中图分类号： R273
- 纸质出版日期：2023-11-30，
  
  收稿日期：2022-12-10，
- 稿件说明：
移动端阅览
王郅宜, 高磊, 胡少朴, 等. 从正邪理论探讨肿瘤免疫微环境及中医辨治思路[J]. 现代中医临床, 2023,30(6):71-75.

WANG Zhiyi, GAO Lei, HU Shaopu, et al. Discussion on tumor immune microenvironment and the application of traditional Chinese medicine based on the theory of "healthy and evil qi"[J]. Modern Chinese Clinical Medicine, 2023,30(6):71-75.
王郅宜, 高磊, 胡少朴, 等. 从正邪理论探讨肿瘤免疫微环境及中医辨治思路[J]. 现代中医临床, 2023,30(6):71-75. DOI： 10.3969/j.issn.2095-6606.2023.06.016.

WANG Zhiyi, GAO Lei, HU Shaopu, et al. Discussion on tumor immune microenvironment and the application of traditional Chinese medicine based on the theory of "healthy and evil qi"[J]. Modern Chinese Clinical Medicine, 2023,30(6):71-75. DOI： 10.3969/j.issn.2095-6606.2023.06.016.

摘要

肿瘤免疫微环境(TIME)在肿瘤的发生发展及治疗转归中具有重要作用。TIME始终处于抗肿瘤与促肿瘤的动态对抗过程中，与中医学正邪理论具有内在一致性。根据各种免疫细胞、细胞因子、趋化因子等在肿瘤发生发展的作用，可将其归属于“正气”与“邪气”的范畴，即能够增强机体抗肿瘤免疫功能，抑制肿瘤增殖、生长、转移的因素为正气；破坏机体免疫稳态，抑制抗肿瘤免疫功能或增强促肿瘤功能的因素则为邪气。肿瘤的发生是正邪失衡、邪气占据主导地位所致。肿瘤免疫抑制微环境的形成可视作正邪相搏，邪胜于正的微观体现。正气化邪在肿瘤免疫抑制微环境的形成过程中发挥重要作用。其中，扶正主要通过补益人体正气，增强正向免疫细胞活性及浸润状态，提高机体抗肿瘤免疫。祛邪类中药可抑制负向免疫细胞的极化，缓解免疫抑制状态，以实现扶正目的。基于TIME中正邪相互转化的关系，可充分发挥中医药纠偏复正的优势。

Abstract

Tumor immune microenvironment (TIME) plays an important role in the development and treatment outcome of tumors. TIME is always in the dynamic confrontation process of anti-tumor and tumor promotion

has consistency with the theory of "healthy and evil qi" in traditional Chinese medicine. According to the role of various immune cells

cytokines

chemokines in tumor development

they can be classified to the "healthy qi" and "evil qi" . The factors that can enhance the anti-tumor immune function and inhibit the tumor proliferation

growth and metastasis belong to the category of healthy qi

while those that destroy the immune homeostasis

inhibit the anti-tumor immune function or enhance the pro-tumor function are evil qi. The occurrence of tumor is caused by the imbalance of healthy and evil qi and the dominant position of the evil side. The formation of tumor immunosuppressive microenvironment can be regarded as the micro embodiment of the combat between the two sides

in which the evil defeats the healthy. Resolving evil by healthy qi plays an important role in the formation of the tumor immunosuppressive microenvironment. Reinforcing healthy qi is a method to supplement the healthy factors

enhances the activity and infiltration state of immune cells

and improves the body’s anti-tumor immunity. Traditional Chinese medicine can inhibit the polarization of negative immune cells and relieve the state of immune suppression

so as to achieve this purpose. Based on the relationship between the healthy and evil qi in TIME

the advantages of TCM rectifying and correcting can be fully played.

关键词

正邪肿瘤免疫微环境扶正祛邪

Keywords

healthy and evil qitumorimmune microenvironmentreinforce healthy qidispel evil

references

曹毛毛，陈万青.GLOBOCAN 2020全球癌症统计数据解读[J].中国医学前沿杂志(电子版)，2021, 13(3): 63-69.

SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021, 71(3): 209-249.

汤钊猷.肝癌治疗的“消灭与改造并举”策略[J].实用肝脏病杂志，2015, 18(2): 113-114.

李杰，郭秋均，林洪生.中医药对肿瘤免疫抑制微环境的调控作用及分子机制研究[J].世界中医药，2014, 9(7): 845-850,856.

詹文涛. 正邪分争论探讨[J].云南中医杂志，1986, 7(2): 12-14.

孙广仁，郑洪新. 中医基础理论[M]. 3版. 北京：中国中医药出版社, 2012: 246-247.

LV B，WANG Y，MA D，et al. Immunotherapy：reshape the tumor immune microenvironment[J/OL]. Front Immunol，2022, 13: 844142[2022-11-10]. https://www.frontiersin.org/articles/10.3389/fimmu.2022.844142/fullhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.844142/full.

杨丽惠，胡凯文，王婧筱.基于肝癌免疫微环境探讨活血化痰解毒法在肝癌中的作用机制[J]. 中国实验方剂学杂志，2022, 28(14): 172-178.

李中梓. 医宗必读[M].北京：中国中医药出版社, 2020: 256.

陈钢. 正邪关系补论[J].成都中医药大学学报，2005, 28(1): 1-3.

刘燕，吴耀松，刘俊，等. 从正邪转化探讨肿瘤病机与治疗[J].北京中医药大学学报，2021, 44(2): 183-187.

宫锡杭，陈受强.《内经》正邪离合论与中医病邪理论的气化观[J].甘肃中医学院学报，1996, 13(1): 3-5.

盛寅. 医经秘旨[M].张挹芳，点注.南京：江苏科学技术出版社, 1984: 44.

郁仁存，唐武军.平衡学说在肿瘤综合治疗中的应用[J]. 癌症进展，2004, 2(6): 438-440.

沈金鳌. 杂病源流犀烛[M].李占永，李晓林，校注.北京：中国中医药出版社, 1994: 215.

何立丽，孙桂芝.孙桂芝关于恶性肿瘤病因病机“二本”学说[J].中国中医药信息杂志，2010, 17(1): 88-89.

GUBIN M M，VESELY M D. Cancer immunoediting in the era of immuno-oncology[J]. Clin Cancer Res，2022, 28(18): 3917-3928.

DESAI ，COXON A T，DUNN G P. Therapeutic applications of the cancer immunoediting hypothesis[J/OL]. Semin Cancer Biol，2022, 78: 63-77[2022-11-10]. https://www.sciencedirect.com/science/article/abs/pii/S1044579X21000523https://www.sciencedirect.com/science/article/abs/pii/S1044579X21000523.

WANG Y，JIA A，BI Y，et al. Targeting myeloid-derived suppressor cells in cancer immunotherapy[J/OL]. Cancers，2020, 12(9): 2626[2022-11-10]. https://www.mdpi.com/2072-6694/12/9/2626https://www.mdpi.com/2072-6694/12/9/2626.

PAN Y，YU Y，WANG X，et al. Tumor-associated macrophages in tumor immunity[J/OL]. Front Immunol，2020, 11: 583084[2022-11-10]. https://www.frontiersin.org/articles/10.3389/fimmu.2020.583084/fullhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.583084/full.

CHANMEE T，ONTONG P，KONNO K，et al. Tumor-associated macrophages as major players in the tumor microenvironment[J]. Cancers(Basel)，2014, 6(3): 1670-1690.

VESELY M D，KERSHAW M H，SCHREIBER R D，et al. Natural innate and adaptive immunity to cancer[J/OL]. Annu Rev Immunol，2011, 29: 235-271[2022-11-10]. https://doi.org/10.1146/annurev-immunol-031210-101324https://doi.org/10.1146/annurev-immunol-031210-101324.

CAMPBELL D J. Control of regulatory T cell migration，function，and homeostasis[J]. J Immunol，2015, 195(6): 2507-2513.

LI C，JIANG P，WEI S，et al. Regulatory T cells in tumor microenvironment：new mechanisms，potential therapeutic strategies and future prospects[J/OL]. Mol Cancer，2020, 19(1): 116[2022-11-10]. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-020-01234-1https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-020-01234-1.

CHEN X，CHEN X，GAO J，et al. Astragaloside III enhances anti-tumor response of NK cells by elevating NKG2D and IFN－Γ[J/OL]. Front Pharmacol，2019, 10: 898[2022-11-10]. https://www.frontiersin.org/articles/10.3389/fphar.2019.00898/fullhttps://www.frontiersin.org/articles/10.3389/fphar.2019.00898/full.

袁梦云，张星星，谢晓东，等. 基于巨噬细胞极化观察白术内酯Ⅱ对胃癌细胞的作用[J]. 中国实验方剂学杂志，2020, 26(21): 100-108.

马旺博，马月，范方田，等. 参芪扶正注射液干预低糖介导的免疫抑制微环境作用及其机制研究[J]. 中国临床药理学与治疗学，2022, 27(2): 136-143.

杨葛俊，邹珏瑶，赵涵，等. 丹参－人参配伍调控MDSCs重塑黑色素瘤免疫微环境的研究[J]. 南京中医药大学学报，2022, 38(8): 717-726.

周波，戴飞跃. 参苓白术散对胃癌IV期患者外周血CD4+CD25+Tregs的影响[J]. 湖南中医药大学学报，2015, 35(5): 50-52.

JIANG X，CAO G，GAO G，et al. Triptolide decreases tumor-associated macrophages infiltration and M2 polarization to remodel colon cancer immune microenvironment via inhibiting tumor-derived CXCL12[J]. J Cell Physiol，2021, 236(1): 193-204.

ZHUANG H，DAI X，ZHANG X，et al. Sophoridine suppresses macrophage-mediated immunosuppression through TLR4/IRF3 pathway and subsequently upregulates CD8+ T cytotoxic function against gastric cancer[J/OL]. Biomedecine Pharmacother，2020, 121: 109636[2022-11-10]. https://www.sciencedirect.com/science/article/pii/S0753332219352588https://www.sciencedirect.com/science/article/pii/S0753332219352588.

CHEN D，YANG Y，YANG P. Quxie capsule inhibits colon tumor growth partially through Foxo1－mediated apoptosis and immune modulation[J/OL]. Integr Cancer Ther，2019, 18: 1534735419846377[2022-11-10]. https://journals.sagepub.com/doi/10.1177/1534735419846377https://journals.sagepub.com/doi/10.1177/1534735419846377.

甘剑峰，张毅靖，谢翔雨，等. 扶正消瘤颗粒对H22荷瘤小鼠的免疫调节及抗肿瘤作用[J]. 中药材，2021, 44(10): 2425-2429.

潘俊杰，陈芳，杨宏宽，等. 清肺解毒汤对小鼠Lewis肺癌皮下移植瘤生长及肿瘤微环境免疫抑制的影响[J]. 中华中医药杂志，2020, 35(11): 5752-5755.

赵元辰，刘瑞，祁鑫，等. 肺瘤平膏对Lewis肺癌小鼠树突状细胞及巨噬细胞的实验研究[J]. 北京中医药，2018, 37(12): 1135-1140.

张介宾. 类经[M]. 北京：人民卫生出版社, 1965: 463.

刘静雯，王瑜，冯媛媛，等. 补肾解毒方调控肿瘤相关巨噬细胞M2极化对大肠癌转移的影响[J]. 中国实验方剂学杂志，2022, 28(17): 60-66.

ZHOU J，LI X，WU X，et al. Exosomes released from tumor-associated macrophages transfer miRNAs that induce a treg/Th17 cell imbalance in epithelial ovarian cancer[J]. Cancer Immunol Res，2018, 6(12): 1578-1592.

刘声，杨国旺，韩冬，等. 益气活血药对肿瘤转移中Treg/Th17细胞漂移所致免疫编辑重塑的调控研究[J]. 中华中医药杂志，2014, 29(6): 1822-1826.

李素素，濮文渊，凌云，等. 三物白散通过影响FXR表达逆转Th1/Th2漂移发挥抗肝癌免疫应答作用[J]. 中医学报，2021, 36(5): 1021-1028.

王爱华，刘维，金玥，等. 人参皂苷Rg3：一种潜在的治疗非小细胞肺癌的天然药物[J].中华中医药学刊，2022, 40(2): 156-159,272.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于“修养宜行外功”探讨肿瘤患者的中医运动疗法

陶广正辨治肿瘤学术经验

王沛教授治疗癌性疼痛的经验

乌梅丸治疗肿瘤免疫疗法相关肠炎探析

李乃卿教授应用扶正固本法治疗肿瘤的临床经验